SUMMARY

• In adult patients with moderate to severe plaque psoriasis (PsO), TREMFYA is administered by subcutaneous injection. The recommended dosage is 100 mg at week 0, week 4, and every 8 weeks thereafter.¹
• In adult patients with active psoriatic arthritis (PsA), TREMFYA is administered by subcutaneous injection. The recommended dosage is 100 mg at week 0, week 4, and every 8 weeks thereafter. TREMFYA may be administered alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) (eg, methotrexate).¹
• In adult patients with moderately to severely active ulcerative colitis (UC), the recommended induction dosage of TREMFYA is 200 mg administered by intravenous infusion over at least one hour at week 0, week 4, and week 8. The recommended maintenance dosage of TREMFYA is 100 mg administered by subcutaneous injection at week 16 and every 8 weeks thereafter, or 200 mg administered by subcutaneous injection at week 12 and every 4 weeks thereafter. Use the lowest effective recommended dosage to maintain therapeutic response.¹
• In adult patients with moderately to severely active Crohn’s disease (CD), the recommended induction dosage of TREMFYA is 200 mg administered by intravenous infusion over at least one hour at Week 0, Week 4, and Week 8, or 400 mg administered by subcutaneous injection (given as two consecutive injections of 200 mg each) at Week 0, Week 4, and Week 8. The recommended maintenance dosage of TREMFYA is 100 mg administered by subcutaneous injection at Week 16, and every 8 weeks thereafter, or 200 mg administered by subcutaneous injection at Week 12, and every 4 weeks thereafter. Use the lowest effective recommended dosage to maintain therapeutic response.¹
• TREMFYA is intended for use under the guidance and supervision of a healthcare professional. TREMFYA may be administered by a healthcare professional, or a patient/caregiver may inject after proper training on correct subcutaneous injection technique.¹
• The TREMFYA Instructions for Use contains more detailed patient instructions on the preparation and administration of TREMFYA.¹

PRODUCT LABELING

DOSAGE AND ADMINISTRATION

Plaque Psoriasis

TREMFYA is administered by subcutaneous injection. The recommended dosage is 100 mg at week 0, week 4, and every 8 weeks thereafter.¹

Psoriatic Arthritis

TREMFYA is administered by subcutaneous injection. The recommended dosage is 100 mg at week 0, week 4, and every 8 weeks thereafter. TREMFYA may be administered alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) (eg, methotrexate).¹

Ulcerative Colitis

The recommended induction dosage of TREMFYA is 200 mg administered by intravenous infusion over at least one hour at week 0, week 4, and week 8.¹

The recommended maintenance dosage of TREMFYA is 100 mg administered by subcutaneous injection at week 16 and every 8 weeks thereafter, or 200 mg administered by subcutaneous injection at week 12 and every 4 weeks thereafter.¹

Use the lowest effective recommended dosage to maintain therapeutic response.¹

Crohn’s Disease

The recommended induction dosage of TREMFYA is 200 mg administered by intravenous infusion over at least one hour at Week 0, Week 4, and Week 8, or 400 mg administered by subcutaneous injection (given as two consecutive injections of 200 mg each) at Week 0, Week 4, and Week 8.¹

The recommended maintenance dosage of TREMFYA is 100 mg administered by subcutaneous injection at Week 16, and every 8 weeks thereafter, or 200 mg administered by subcutaneous injection at Week 12, and every 4 weeks thereafter.¹

Use the lowest effective recommended dosage to maintain therapeutic response.¹

Preparation and Administration Instructions for Subcutaneous Injection

Administer TREMFYA subcutaneously. Each prefilled syringe, One-Press injector, or prefilled pen is for one time use in one patient only. Instruct patients to inject the full amount (1 mL or 2 mL), which provides 100 mg or 200 mg of TREMFYA, respectively.¹

TREMFYA is intended for use under the guidance and supervision of a healthcare professional. TREMFYA may be administered by a healthcare professional, or a patient/caregiver may inject after proper training on correct subcutaneous injection technique.¹

Before injection, remove TREMFYA from the refrigerator and allow to reach room temperature (30 minutes) without removing the needle cap.¹

Inject into the front of the thighs, the lower abdomen except for the 2 inches around the navel, or the back of the upper arms (healthcare professional or caregiver only).¹

Do not inject TREMFYA into areas where the skin is tender, bruised, red, hard, thick, scaly, or affected by psoriasis.¹

The TREMFYA Instructions for Use contains more detailed patient instructions on the preparation and administration of TREMFYA.¹

If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.¹

Inspect TREMFYA visually for particulate matter and discoloration prior to administration. TREMFYA is a clear and colorless to light yellow solution that may contain small translucent particles. Do not use if the liquid contains large particles, is discolored or cloudy. TREMFYA does not contain preservatives; therefore, discard any unused product remaining in the prefilled syringe, One-Press injector, or prefilled pen.¹

Preparation and Administration Instructions for Intravenous Infusion (UC and CD)

Preparation Instructions:¹

1. Withdraw and then discard 20 mL of the 0.9% Sodium Chloride Injection from the 250 mL infusion bag which is equal to the volume of TREMFYA to be added.
2. Withdraw 20 mL of TREMFYA from the vial and add it to the 250 mL intravenous infusion bag of 0.9% Sodium Chloride Injection for a final concentration of 0.8 mg/mL. Gently mix the diluted solution. Discard the vial with any remaining solution.
3. Visually inspect the diluted solution for particulate matter and discoloration before infusion. Infuse the diluted solution over a period of at least one hour.
4. Use only an infusion set with an in-line, sterile, non-pyrogenic, low protein binding filter (pore size 0.2 micrometer).
5. Do not infuse TREMFYA concomitantly in the same intravenous line with other medicinal products.
6. Dispose any unused medicinal product in accordance with local requirements.

Administration Instructions:

• TREMFYA solution for intravenous infusion must be diluted, prepared, and infused by a healthcare professional using aseptic technique. TREMFYA does not contain preservatives. Each vial is for one time use in one patient only.¹
• Inspect TREMFYA visually for particulate matter and discoloration prior to administration. TREMFYA is a clear and colorless to light yellow solution that may contain small translucent particles. Do not use if the liquid contains large particles, is discolored, or is cloudy.¹

PATIENT COUNSELING INFORMATION

Advise the patient and/or caregiver to read the FDA-approved patient labeling (Medication Guide and Instructions for Use) before starting TREMFYA therapy, and each time the prescription is renewed, as there may be new information they need to know.¹

Instruction on Injection Technique

Instruct patients or caregivers to perform the first self-injection under the supervision and guidance of a qualified healthcare professional for proper training in subcutaneous injection technique, including injection of the full dose.¹

Proper Sharps Disposal Instructions

Counsel patients and caregivers on the proper technique of needle and syringe disposal. Instruct patients to dispose needles and syringes in a puncture-resistant container. Advise patients and caregivers not to reuse needles or syringes.¹

Administration Instructions

Instruct patients that if they forget to administer a dose of TREMFYA, then they should administer TREMFYA as soon as they remember. Instruct patients to administer the next dose at the regular scheduled time.¹